Ovarian Cancer

Anixa Biosciences Doses First Ovarian Cancer Patient in Novel Autologous Cell Therapy Trial

Allarity Scraps Dovitinib Single-Agent Plans in Kidney Cancer, Refocuses on Combination Therapies

Sotio Biotech Begins Phase II Trial of IL-15-Targeted Candidate in Solid Tumors

EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca

Tailor Bio Receives £650K UK Biomedical Grant to Develop Predictive Diagnostic for Ovarian Cancer

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials

Akoya Biosciences, Acrivon Therapeutics Partner to Develop CDx

Acrivon Therapeutics to Study CHK1/2 Inhibitor ACR-368, Predictive Diagnostic in Phase II Trial

Nuvectis Cleared by FDA to Begin Phase I Trial of HSF1 Inhibitor in Ovarian Cancer

Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

In Brief This Week: ImmunoGen, Elevation Oncology, Strata Oncology

City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers

Singapore-Based Inex Innovate Receives CE Mark for Rapid Ovarian Cancer Test

Break Through Cancer Awards $50M in Grants for Collaborative Projects in Ovarian, Pancreatic, Brain Cancers

Preclinical Data In Hand, City of Hope to Study Anti-TAG72 CAR T-Cell Therapy for Ovarian Cancer

UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study